Study study type PathologyT1T0Patientssample sizesROB Results

mGC or mGEJC - M - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 negative

versus Standard of Care (SoC)
avelumab alone
JAVELIN Gastric 100, 2020
  NCT02625610
RCTmGC or mGEJC - M - HER2 negativeavelumab maintenancechemotherapypatients with locally advanced or metastatic HER2-negative gastric or gastroesophageal junction cancer. all patients received first-line chemotherapy249 / 250some concern
inconclusive
  • inconclusive 9 % decrease in deaths (OS) (PE)
  • statistically significant 38 % decrease in DCR

mGC or mGEJC - M - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 neg/PDL1 positive

versus Standard of Care (SoC)
avelumab alone
JAVELIN Gastric 100 (PDL1>1%), 2020
  NCT02625610
RCTmGC or mGEJC - M - HER2 neg/PDL1 positiveavelumab maintenancechemotherapypatients with locally advanced or metastatic HER2-negative gastric or gastroesophageal junction cancer. all patients received first-line chemotherapy30 / 24some concern
inconclusive
  • inconclusive 13 % increase in deaths (OS) (PE)